journal
https://read.qxmd.com/read/39030279/bcma-directed-therapy-for-early-relapsed-and-or-refractory-multiple-myeloma
#1
JOURNAL ARTICLE
Niels W C J van de Donk, Sonja Zweegman
No abstract text is available yet for this article.
July 19, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38992122/targeting-chromosomal-instability-in-patients-with-cancer
#2
REVIEW
Duaa H Al-Rawi, Emanuele Lettera, Jun Li, Melody DiBona, Samuel F Bakhoum
Chromosomal instability (CIN) is a hallmark of cancer and a driver of metastatic dissemination, therapeutic resistance, and immune evasion. CIN is present in 60-80% of human cancers and poses a formidable therapeutic challenge as evidenced by the lack of clinically approved drugs that directly target CIN. This limitation in part reflects a lack of well-defined druggable targets as well as a dearth of tractable biomarkers enabling direct assessment and quantification of CIN in patients with cancer. Over the past decade, however, our understanding of the cellular mechanisms and consequences of CIN has greatly expanded, revealing novel therapeutic strategies for the treatment of chromosomally unstable tumours as well as new methods of assessing the dynamic nature of chromosome segregation errors that define CIN...
July 11, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38982247/is-netter-2-a-practice-changing-trial
#3
JOURNAL ARTICLE
Jonathan Strosberg, Mauro Cives
No abstract text is available yet for this article.
July 9, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38965396/emerging-advances-in-defining-the-molecular-and-therapeutic-landscape-of-small-cell-lung-cancer
#4
REVIEW
Triparna Sen, Nobuyuki Takahashi, Subhamoy Chakraborty, Naoko Takebe, Amin H Nassar, Nagla A Karim, Sonam Puri, Abdul Rafeh Naqash
Small-cell lung cancer (SCLC) has traditionally been considered a recalcitrant cancer with a dismal prognosis, with only modest advances in therapeutic strategies over the past several decades. Comprehensive genomic assessments of SCLC have revealed that most of these tumours harbour deletions of the tumour-suppressor genes TP53 and RB1 but, in contrast to non-small-cell lung cancer, have failed to identify targetable alterations. The expression status of four transcription factors with key roles in SCLC pathogenesis defines distinct molecular subtypes of the disease, potentially enabling specific therapeutic approaches...
July 4, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38961233/just-scratching-the-surface-novel-treatment-approaches-for-multiple-myeloma-targeting-cell-membrane-proteins
#5
REVIEW
Paola Neri, NoƩmie Leblay, Holly Lee, Annamaria Gulla, Nizar J Bahlis, Kenneth C Anderson
A better understanding of the roles of the adaptive and innate immune systems in the oncogenesis of cancers including multiple myeloma (MM) has led to the development of novel immune-based therapies. B cell maturation antigen (BCMA), G protein-coupled receptor family C group 5 member D (GPRC5D) and Fc receptor-like protein 5 (FcRL5, also known as FcRH5) are cell-surface transmembrane proteins expressed by plasma cells, and have been identified as prominent immunotherapeutic targets in MM, with promising activity demonstrated in patients with heavily pretreated relapsed and/or refractory disease...
July 3, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38918596/asciminib-is-safe-and-effective-in-patients-with-newly-diagnosed-cml
#6
JOURNAL ARTICLE
Diana Romero
No abstract text is available yet for this article.
June 25, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38914834/vimseltinib-improves-outcomes-in-tenosynovial-giant-cell-tumour
#7
JOURNAL ARTICLE
David Killock
No abstract text is available yet for this article.
June 24, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38907078/niche-2-validates-the-efficacy-of-neoadjuvant-icis-in-dmmr-colon-cancer
#8
JOURNAL ARTICLE
David Killock
No abstract text is available yet for this article.
June 21, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38907077/promising-outcomes-with-liso-cel-in-patients-with-r-r-follicular-lymphoma
#9
JOURNAL ARTICLE
Diana Romero
No abstract text is available yet for this article.
June 21, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38890555/isatuximab-vrd-quadruplet-shows-promise-in-transplant-ineligible-ndmm
#10
JOURNAL ARTICLE
David Killock
No abstract text is available yet for this article.
June 18, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38886613/addition-of-sintilimab-to-standard-therapy-improves-event-free-survival
#11
JOURNAL ARTICLE
Peter Sidaway
No abstract text is available yet for this article.
June 17, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38886612/osimertinib-efficacious-as-maintenance-therapy-in-patients-with-stage-iii-nsclc
#12
JOURNAL ARTICLE
Peter Sidaway
No abstract text is available yet for this article.
June 17, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38877176/neoadjuvant-ipilimumab-nivolumab-superior-to-adjuvant-nivolumab
#13
JOURNAL ARTICLE
Peter Sidaway
No abstract text is available yet for this article.
June 14, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38849530/towards-equitable-ai-in-oncology
#14
REVIEW
Vidya Sankar Viswanathan, Vani Parmar, Anant Madabhushi
Artificial intelligence (AI) stands at the threshold of revolutionizing clinical oncology, with considerable potential to improve early cancer detection and risk assessment, and to enable more accurate personalized treatment recommendations. However, a notable imbalance exists in the distribution of the benefits of AI, which disproportionately favour those living in specific geographical locations and in specific populations. In this Perspective, we discuss the need to foster the development of equitable AI tools that are both accurate in and accessible to a diverse range of patient populations, including those in low-income to middle-income countries...
June 7, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38840029/exploiting-bacteria-for-cancer-immunotherapy
#15
REVIEW
Seong-Young Kwon, Hien Thi-Thu Ngo, Jinbae Son, Yeongjin Hong, Jung-Joon Min
Immunotherapy has revolutionized the treatment of cancer but continues to be constrained by limited response rates, acquired resistance, toxicities and high costs, which necessitates the development of new, innovative strategies. The discovery of a connection between the human microbiota and cancer dates back 4,000 years, when local infection was observed to result in tumour eradication in some individuals. However, the true oncological relevance of the intratumoural microbiota was not recognized until the turn of the twentieth century...
June 5, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38822215/bispecific-and-multispecific-antibodies-in-oncology-opportunities-and-challenges
#16
REVIEW
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf Bargou
Research into bispecific antibodies, which are designed to simultaneously bind two antigens or epitopes, has advanced enormously over the past two decades. Owing to advances in protein engineering technologies and considerable preclinical research efforts, bispecific antibodies are constantly being developed and optimized to improve their efficacy and to mitigate toxicity. To date, >200 of these agents, the majority of which are bispecific immune cell engagers, are in either preclinical or clinical evaluation...
May 31, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38816606/radicals-hd-sheds-light-on-the-role-of-adt-addition-to-post-operative-radiotherapy
#17
JOURNAL ARTICLE
Diana Romero
No abstract text is available yet for this article.
May 30, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38806653/ponatinib-superior-to-imatinib-in-ph-all
#18
JOURNAL ARTICLE
Peter Sidaway
No abstract text is available yet for this article.
May 28, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38789564/adding-ibrutinib-to-frontline-therapy-improves-outcomes-in-transplant-eligible-patients-with-mcl
#19
JOURNAL ARTICLE
David Killock
No abstract text is available yet for this article.
May 24, 2024: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/38778084/gaining-ground-in-personalized-breast-cancer-therapy-lesson-learned-from-phergain
#20
JOURNAL ARTICLE
Maria Vittoria Dieci, Valentina Guarneri
No abstract text is available yet for this article.
May 22, 2024: Nature Reviews. Clinical Oncology
journal
journal
20200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.